SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it will submit a contract response to a BROAD AGENCY ANNOUNCEMENT (BAA) solicitation entitled “Application of Platform Technologies for the Development of Therapeutic Agents for Biodefense”. This solicitation (DMID-NIAID-NIHAI20080022BARDA) represents a partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the recently established Biomedical Advanced Research and Development Authority (BARDA) to award contracts that fund the development and evaluation of innovative approaches to treat NIAID category A, B and C bioterror threats. Contract recipients will be awarded up to five years of funding directed toward activities including, research, clinical programs, and the establishment of large-scale manufacturing protocols. The submission deadline is June 4, 2008. A significant emphasis of the contract solicitation is to aid in the development of broad-spectrum therapies able to demonstrate effectiveness against multiple bioterror pathogens and toxins.
